Craft

PharmaEssentia

Stock Price

NT$320

2024-03-27

Market Capitalization

NT$106.2 B

2024-03-27

Revenue

NT$9.7 B

FY, 2024

PharmaEssentia Summary

Company Summary

Overview
PharmaEssentia (藥華醫藥股份有限公司) is a biotech company focused on the areas of hematology, oncology, dermatology, and infectious diseases. Its lead compound is Ropeginterferon alfa-2b, an interferon for hepatitis. The company also develops treatments for gastric, gastro-esophageal, esophageal, and breast cancer, as well as psoriasis.
Type
Public
Status
Active
Founded
2003
HQ
Taipei, TW | view all locations
Website
https://hq.pharmaessentia.com/en
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Chingleou Teng

    Chingleou Teng, Chairperson and Chief Pharmaceutical Officer

    • Ko-Chung Lin

      Ko-Chung Lin, Founder and Chief Executive Officer

      • Jack Hwang

        Jack Hwang, General Manager

        • Albert Qin

          Albert Qin, Chief Medical Officer

          LocationsView all

          5 locations detected

          • Taipei, Taipei City HQ

            Taiwan

            13F, No. 3, Park St.

          • Burlington, MA

            United States

            35 Corporate Dr #325

          • Beijing

            China

            Chaoyang

          • Shinjuku City, Tōkyō-to

            Japan

            2-chōme-5-12 Shinjuku

          • Taichung City

            Taiwan

            3F, No. 6, Zhongke Rd, Xitun District

          PharmaEssentia Financials

          Summary Financials

          Revenue (FY, 2024)
          NT$9.7B
          Gross profit (FY, 2024)
          NT$8.9B
          Net income (FY, 2024)
          NT$3.0B
          Cash (FY, 2024)
          NT$21.1B
          EBIT (FY, 2024)
          NT$1.7B
          Enterprise value
          $86.1B

          Footer menu